Chargement en cours...
Phase 1 Study of Alisertib (MLN8237) and Weekly Irinotecan in Adults with Advanced Solid Tumors
PURPOSE: Aurora kinases are overexpressed or amplified in numerous malignancies. This study was designed to determine the safety and tolerability of the Aurora A kinase inhibitor alisertib (MLN8237) when combined with weekly irinotecan. METHODS: In this single center phase 1 study, adult patients wi...
Enregistré dans:
| Publié dans: | Cancer Chemother Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8259450/ https://ncbi.nlm.nih.gov/pubmed/33993383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04293-3 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|